Dr Richard Sloan
My laboratory aims to identify and characterise host encoded antiviral factors that inhibit HIV and other retroviruses.
Dr Richard Sloan is a Lecturer in Infection Medicine and holds a joint appointment at the Zhejiang University - University of Edinburgh Institute (ZJU-UoE) in Haining China. After undergraduate studies at the University of Edinburgh Richard obtained his PhD degree from University College London (UCL) in 2007 and then undertook postdoctoral research at the McGill University AIDS Centre in Montreal. He started his own lab at Barts and The London School of Medicine in 2013, before moving up to Edinburgh University to continue his research in the Division of Infection and Pathway Medicine in 2016.
My primary teaching responsibility is in the areas of immunology and infectious disease for Biomedical Sciences undergraduate students at the Zhejiang University and Edinburgh University joint institute (ZJU-UoE Institute) in Haining, China.
I also contribute to our online Clinical Microbiology & Infectious Diseases MSc, and other undergraduate infection and immunology courses based in Edinburgh. While our research group hosts a number of masters, undergraduate, and summer student research projects.
We aim to understand how cell intrinsic innate immunity inhibits HIV and similar viruses. Host cells express a variety of antiviral factors that directly inhibit viral infection, these are often inducible by type-I interferons, or may be basally expressed. By identifying and understanding these antiviral factors we can develop new paradigms in antiviral therapy and understand viral disease susceptibility within individuals and populations.
We are interested in a number of these antiviral factors, including IFITM proteins, REAF/RPRD2 and the HUSH complex, which block viral entry, reverse transcription and repress transcription respectively. More recently we have become interested in how endogenous retroelements may be similarly controlled by antiviral factors and how this may influence inflammatory disease.
Current Funding Sources
- Dr Aine McKnight, Barts and The London School of Medicine and Dentistry
- Dr Chen Liang, McGill University Montreal
- Dr Jose Garcia-Perez, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh
- Dr Linrong Lu, ZJU-UoE Institute, Zhejiang University
- Phosphatase PP2A is essential for TH17 differentiation. Qin Xu, Xuexiao Jin, Mingzhu Zheng, Deepak Rohila, Guotong Fu, Zhuoyu Wen, Jun Lou, Songquan Wu, Richard Sloan, Lie Wang, Hu Hu, Xiang Gao, and Linrong Lu. (2019). Proceedings of the National Academy of Sciences (PNAS). 116 (3) 982-987. https://doi.org/10.1073/pnas.1807484116
- HIV-1 Vpr accessory protein interacts with REAF and mitigates its associated anti-viral activity. Gibbons J, Marno K, Lee WY, Jones C, Ogunkolade W, Sloan RD, McKnight A. (2018) bioRxiv preprint server. https://doi.org/10.1101/408161
- IFITM proteins inhibit HIV protein synthesis. (2018) Lee WY, Fu RM, Liang C, Sloan RD. Scientific Reports. 8: 14551, https://doi.org/10.1038/s41598-018-32785-
- RNA-Associated Early-Stage Antiviral Factor Is a Major Component of Lv2 Restriction. Marno KM, O'Sullivan E, Jones CE, Díaz-Delfín J, Pardieu C, Sloan RD, McKnight Á. (2017). Journal of Virology. 91(10). e01228-16. https://doi.org/10.1128/JVI.01228-16
- Productive entry of HIV-1 during cell-to-cell transmission via dynamin-dependent endocytosis. (2013). Sloan RD, Kuhl BD, Mesplede TM, Donahue DA, Munch J, Wainberg MA. Journal of Virology. 87(14):8110-23. https://doi.org/10.1128/JVI.00815-13
- The Viral Protein Tat Can Inhibit the Establishment of HIV-1 Latency. Donahue DA, Kuhl BD, Sloan RD, Wainberg MA. (2012). Journal of Virology. 86(6):3253-63. https://doi.org/10.1128/JVI.06648-11
- Transcription of preintegrated HIV-1 cDNA modulates expression of cell surface major histocompatibility complex class-I via Nef. Sloan RD, Kuhl BD, Donahue DA, Roland A, Bar-Magen T, Wainberg MA. (2011). Journal of Virology. 85(6):2828-36. https://doi.org/10.1128/JVI.01854-10
- Tetherin restricts direct cell-to-cell infection of HIV-1. Kuhl BD, Sloan RD, Donahue DA, Bar-Magen T, Liang C, Wainberg MA. (2010). Retrovirology. 24;7:115. https://doi.org/10.1186/1742-4690-7-115
- Identification of Novel Mutations Responsible for Resistance to MK-2048, a Second-Generation HIV-1 Integrase inhibitor. Bar-Magen T, Sloan RD, Donahue DA, Kuhl BD, Zabeida A, Oliveira M, Hazuda DJ, Wainberg MA. (2010). Journal of Virology. 84(18):9210-6. https://doi.org/10.1128/JVI.01164-10
- Antiviral resistance mutations potentiate hepatitis B virus immune evasion through disruption of its surface antigen a determinant. Sloan RD, Ijaz S, Moore PL, Harrison TJ, Teo CG, Tedder RS. (2008). Antivir Ther. 13(3):439-47. https://www.intmedpress.com/serveFile.cfm?sUID=1f016a49-8945-4edd-94fc-5049b7dba9f3